Item 8.01. Other Events.

On July 14, 2022, BeiGene, Ltd. ("BeiGene") announced that the U.S. Food and Drug Administration (FDA) has deferred action on the Biologics License Application (BLA) for tislelizumab as a second-line (2L) treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press release titled "BeiGene Provides Regulatory Update on the U.S.
                          Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L
                          ESCC" issued by BeiGene, Ltd. on July 14, 2022

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses